keyword
https://read.qxmd.com/read/38558446/germacrone-alleviates-breast-cancer-associated-osteolysis-by-inhibiting-osteoclastogenesis-via-inhibition-of-mapk-nf-%C3%AE%C2%BAb-signaling-pathways
#21
JOURNAL ARTICLE
Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang
Bone is one of the most frequent sites for metastasis in breast cancer patients. Bone metastasis significantly reduces the survival time and the life quality of breast cancer patients. Germacrone (GM) can serve humans as an anti-cancer and anti-inflammation agent, but its effect on breast cancer-induced osteolysis remains unclear. This study aims to investigate the functions and mechanisms of GM in alleviating breast cancer-induced osteolysis. The effects of GM on osteoclast differentiation, bone resorption, F-actin ring formation, and gene expression were examined in vitro...
April 1, 2024: Phytotherapy Research: PTR
https://read.qxmd.com/read/38556044/erianin-serves-as-an-nfatc1-inhibitor-to-prevent-breast-cancer-induced-osteoclastogenesis-and-bone-destruction
#22
JOURNAL ARTICLE
Jiehuang Zheng, Weili He, Yan Chen, Lihong Li, Qinghe Liang, Wenqi Dai, Ruopeng Li, Fengsheng Chen, Ziye Chen, Yanhui Tan, Xiaojuan Li
INTRODUCTION: Breast cancer-related bone metastasis can lead to skeletal-related events (SREs), which decrease patient quality of life. Inhibition of osteoclastogenesis is a key treatment for SREs; however, the availability of clinical drugs remains limited, and all existing ones disrupt physiological bone formation, while exhibiting no effect on patient survival time. OBJECTIVES: This study aimed to identify a novel osteoclast inhibitor for the treatment of breast cancer-induced SREs...
March 29, 2024: Journal of Advanced Research
https://read.qxmd.com/read/38554305/outcomes-of-the-patients-with-metastatic-male-breast-cancer
#23
JOURNAL ARTICLE
Izzet Dogan, Nijat Khanmammadov, Selnur Ozkurt, Adnan Aydiner, Pinar Saip
BACKGROUND: The goal of this research is to investigate the clinical characteristics and prognosis of men with metastatic breast cancer (mMBC). METHODS: A retrospective analysis of the data of 28 patients was conducted. Kaplan-Meier and Cox regression analyses were used to assess overall survival (OS) and prognostic variables. RESULTS: At the time of diagnosis, the median age was 57 years (range 26-86). The most prevalent pathological subtype was invasive ductal carcinoma (92...
January 1, 2024: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38550395/the-osteoblast-in-regulation-of-tumor-cell-dormancy-and-bone-metastasis
#24
JOURNAL ARTICLE
Jennifer Zarrer, Hanna Taipaleenmäki
Breast and prostate cancer are among the most common malignancies worldwide. After treatment of the primary tumor, distant metastases often occur after a long disease-free interval. Bone is a major site for breast and prostate cancer metastasis and approximately 70% of patients with advanced disese suffer from osteolytic or osteoblastic bone metastases, a stage at which the disease is incurable. In bone, the disseminated tumor cells (DTCs) can become quiescent or "dormant", a state where they are alive but not actively dividing...
April 2024: Journal of Bone Oncology
https://read.qxmd.com/read/38542380/a-representative-clinical-course-of-progression-with-molecular-insights-of-hormone-receptor-positive-her2-negative-bone-metastatic-breast-cancer
#25
REVIEW
Elizabeth Magno, Karen M Bussard
Despite treatment advances, breast cancer remains a leading cause of death of women in the United States, mostly due to metastatic disease. Bone is a preferential site for breast cancer metastasis, and most metastatic breast cancer patients experience bone involvement at the time of death. The majority of patients with bone metastatic breast cancer are first diagnosed with and treated for early-stage disease, and from development of early-stage breast cancer to the recurrence of cancer in the bones, up to 30 years may elapse...
March 17, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38537211/68ga-dota-iba-uptake-in-breast-cancer
#26
JOURNAL ARTICLE
Feifan Xiang, Huipan Liu, Xiaoqi Tan, Yue Chen
A 77-year-old woman with recently diagnosed breast cancer underwent 68Ga-labeled DOTA-ibandronic acid (68Ga-DOTA-IBA) PET/CT scan for the evaluation of bone metastases. The examination revealed increased tracer uptake, indicating that the cervical vertebrae presented osteoblastic metastasis. Interestingly, the breast cancer also showed enhanced activity of 68Ga-DOTA-IBA.
March 25, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38537210/treatment-of-bone-metastases-of-breast-cancer-with-177lu-dota-iba
#27
JOURNAL ARTICLE
Jia Deng, Jian Yang, Zixuan Cheng, Yue Chen
Bone metastasis of breast cancer often presents as osteolytic. 177Lu-DOTA-ibandronic acid (177Lu-DOTA-IBA) is a new radioactive drug for bone metastasis lesion. We report a case of recurrent intermittent pain due to bone metastasis, who demonstrated a satisfactory therapy response after 2 cycles of 177Lu-DOTA-IBA. In addition, the patient did not have any observable adverse effects.
March 25, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38532155/customised-pre-operative-cranioplasty-to-achieve-maximal-surgical-resection-of-tumours-with-osseous-involvement-a-case-series
#28
JOURNAL ARTICLE
Swati Jain, Adel Helmy, Thomas Santarius, Nicola Owen, Kirsty Grieve, Peter Hutchinson, Ivan Timofeev
PURPOSE: Surgical resection with bony margins would be the treatment of choice for tumours with osseous involvement such as meningiomas and metastasis. By developing and designing pre-operative customised 3D modelled implants, the patient can undergo resection of meningioma and repair of bone defect in the same operation. We present a generalisable method for designing pre-operative cranioplasty in patients to repair the bone defect after the resection of tumours. MATERIALS AND METHODS: We included six patients who presented with a tumour that was associated with overlying bone involvement...
March 27, 2024: Acta Neurochirurgica
https://read.qxmd.com/read/38522564/morusin-inhibits-breast-cancer-induced-osteolysis-by-decreasing-phosphatidylinositol-3-kinase-pi3k-mtor-signalling
#29
JOURNAL ARTICLE
Long Zhang, Weibin Li, Xiaohui Chen, Dongmin Cao, Siyuan You, Fan Shi, Zhengqiong Luo, Hongyu Li, Xiangchen Zeng, Yabin Song, Na Li, Yoshie Akimoto, Gang Rui, Yu Chen, Zuoxing Wu, Ren Xu
Bone metastases caused by breast cancer pose a major challenge to the successful treatment of breast cancer patients. Many researchers have suggested that herbal medicines are extremely effective at preventing and treating cancer-associated osteolysis. Previous studies have revealed that Morusin (MOR) is cytotoxic to many cancer cells ex vivo. Nevertheless, how MOR contributes to osteolysis induced by breast cancer is still unknown, and the potential mechanism of action against osteolysis is worthy of further study...
March 22, 2024: Chemico-biological Interactions
https://read.qxmd.com/read/38508239/cancer-specific-dose-and-fractionation-schedules-in-stereotactic-body-radiotherapy-for-oligometastatic-disease-an-interim-analysis-of-the-eortc-estro-e-2-radiate-oligocare-study
#30
JOURNAL ARTICLE
Sebastian M Christ, Filippo Alongi, Umberto Ricardi, Marta Scorsetti, Lorenzo Livi, Panagiotis Balermpas, Yolande Lievens, Pètra Braam, Barbara Alicja Jereczek-Fossa, Karin Stellamans, Ivica Ratosa, Joachim Widder, Heike Peulen, Piet Dirix, Samuel Bral, Sara Ramella, Hossein Hemmatazad, Kaouthar Khanfir, Xavier Geets, Paul Jeene, Thomas Zilli, Beatrice Fournier, Giovanni Battista Ivaldi, Enrico Clementel, Catherine Fortpied, Felix Boakye Oppong, Piet Ost, Matthias Guckenberger
BACKGROUND AND INTRODUCTION: Optimal dose and fractionation in stereotactic body radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim analysis of OligoCare, we analyzed factors associated with SBRT dose and fractionation. MATERIALS AND METHODS: Analysis was based on the first 1,099 registered patients. SBRT doses were converted to biological effective doses (BED) using α/β of 10 Gy for all primaries, and cancer-specific α/β of 10 Gy for non-small cell lung and colorectal cancer (NSCLC, CRC), 2...
March 18, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38503157/c-met-pathway-in-human-malignancies-and-its-targeting-by-natural-compounds-for-cancer-therapy
#31
REVIEW
Chakrabhavi Dhananjaya Mohan, Muthu K Shanmugam, Siddegowda Gopalapura Shivanne Gowda, Arunachalam Chinnathambi, Kanchugarakoppal S Rangappa, Gautam Sethi
BACKGROUND: c-MET is a receptor tyrosine kinase which is classically activated by HGF to activate its downstream signaling cascades such as MAPK, PI3K/Akt/mTOR, and STAT3. The c-MET modulates cell proliferation, epithelial-mesenchymal transition (EMT), immune response, morphogenesis, apoptosis, and angiogenesis. The c-MET has been shown to serve a prominent role in embryogenesis and early development. The c-MET pathway is deregulated in a broad range of malignancies, due to overexpression of ligands or receptors, genomic amplification, and MET mutations...
January 18, 2024: Phytomedicine
https://read.qxmd.com/read/38499995/bone-endosteal-mimics-regulates-breast-cancer-development-and-phenotype
#32
JOURNAL ARTICLE
Noa Ben Ghedalia Peled, Dane K Hoffman, Livnat Barsky, Noy S Zer, Katya Amar, Hanna Rapaport, Levi A Gheber, Xiang H-F Zhang, Razi Vago
Bone is a frequent site for metastatic development in various cancer types, including breast cancer, with a grim prognosis due to the distinct bone environment. Despite considerable advances, our understanding of the underlying processes leading to bone metastasis progression remains elusive. Here, we applied a bioactive three-dimensional (3D) model capable of mimicking the endosteal bone microenvironment. MDA-MB-231 and MCF7 breast cancer cells were cultured on the scaffolds, and their behaviors and the effects of the biomaterial on the cells were examined over time...
March 18, 2024: Biomacromolecules
https://read.qxmd.com/read/38493144/long-noncoding-rna-malat1-protects-against-osteoporosis-and-bone-metastasis
#33
JOURNAL ARTICLE
Yang Zhao, Jingyuan Ning, Hongqi Teng, Yalan Deng, Marisela Sheldon, Lei Shi, Consuelo Martinez, Jie Zhang, Annie Tian, Yutong Sun, Shinichi Nakagawa, Fan Yao, Hai Wang, Li Ma
MALAT1, one of the few highly conserved nuclear long noncoding RNAs (lncRNAs), is abundantly expressed in normal tissues. Previously, targeted inactivation and genetic rescue experiments identified MALAT1 as a suppressor of breast cancer lung metastasis. On the other hand, Malat1-knockout mice are viable and develop normally. On a quest to discover the fundamental roles of MALAT1 in physiological and pathological processes, we find that this lncRNA is downregulated during osteoclastogenesis in humans and mice...
March 16, 2024: Nature Communications
https://read.qxmd.com/read/38489269/de-novo-steroidogenesis-in-tumor-cells-drives-bone-metastasis-and-osteoclastogenesis
#34
JOURNAL ARTICLE
Luca F Sandor, Joon B Huh, Peter Benko, Toru Hiraga, Szilard Poliska, Csaba Dobo-Nagy, Joanna P Simpson, Natalie Z M Homer, Bidesh Mahata, David S Gyori
Osteoclasts play a central role in cancer-cell-induced osteolysis, but the molecular mechanisms of osteoclast activation during bone metastasis formation are incompletely understood. By performing RNA sequencing on a mouse breast carcinoma cell line with higher bone-metastatic potential, here we identify the enzyme CYP11A1 strongly upregulated in osteotropic tumor cells. Genetic deletion of Cyp11a1 in tumor cells leads to a decreased number of bone metastases but does not alter primary tumor growth and lung metastasis formation in mice...
March 13, 2024: Cell Reports
https://read.qxmd.com/read/38484298/deciphering-breast-cancer-metastasis-cascade-a-systems-biology-approach-integrating-transcriptome-and-interactome-insights-for-target-discovery
#35
JOURNAL ARTICLE
Bikashita Kalita, Mohane Selvaraj Coumar
Breast cancer is the lead cause of cancer-related deaths among women globally. Breast cancer metastasis is a complex and still inadequately understood process and a key dimension of mortality attendant to breast cancer. This study reports dysregulated genes across metastatic stages and tissues, shedding light on their molecular interplay in disease pathogenesis and new possibilities for drug discovery. Comprehensive analyses of gene expression data from primary breast tumor, circulating tumor cells, and distant metastatic sites in the brain, lung, liver, and bone were conducted...
March 14, 2024: Omics: a Journal of Integrative Biology
https://read.qxmd.com/read/38479545/epiberberine-inhibits-bone-metastatic-breast-cancer-induced-osteolysis
#36
JOURNAL ARTICLE
Chengming Wei, Meina Shi, Zi Wang, Wenjian Lan, Na Feng, Fuming Zhang, Jiachen Liu, Jing-Yu Lang, Wanjun Lin, Wenzhe Ma
ETHNOPHARMACOLOGICAL RELEVANCE: Coptidis Rhizoma (Huanglian) is the dried rhizome from the Coptis chinensis Franch. The anti-tumor related diseases of Coptidis Rhizoma were correlated with its traditional use of removing damp-heat, clearing internal fire, and counteracting toxicity. In the recent years, Coptidis Rhizoma and its components have drawn extensive attention toward their anti-tumor related diseases. Besides, Coptidis Rhizoma is traditionally used as an anti-inflammatory herb...
March 11, 2024: Journal of Ethnopharmacology
https://read.qxmd.com/read/38476641/the-role-of-ki-67-in-hr-her2-breast-cancer-a-real-world-study-of-956-patients
#37
JOURNAL ARTICLE
Qin Ma, Yao-Bang Liu, Tong She, Xin-Lan Liu
OBJECTIVE: This study determined the cut-off value of Ki-67 expression and discussed the interaction between Ki-67 and histological grade, further explored the prognostic role of Ki-67 in hormone receptor-positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer;. MATERIALS AND METHODS: We assessed the Ki-67 expression of 956 patients with HR+/HER2 breast cancer diagnosed in the General Hospital of Ningxia Medical University from 2015 to 2019 by immunohistochemistry (IHC), The disease-free survival (DFS) was defined as the time from postoperative to the first local recurrence, distant metastasis or death of the disease...
2024: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/38474093/bridging-the-gap-in-understanding-bone-metastasis-a-multifaceted-perspective
#38
REVIEW
Basant Elaasser, Nour Arakil, Khalid S Mohammad
The treatment of patients with advanced cancer poses clinical problems due to the complications that arise as the disease progresses. Bone metastases are a common problem that cancer patients may face, and currently, there are no effective drugs to treat these individuals. Prostate, breast, and lung cancers often spread to the bone, causing significant and disabling health conditions. The bone is a highly active and dynamic tissue and is considered a favorable environment for the growth of cancer. The role of osteoblasts and osteoclasts in the process of bone remodeling and the way in which their interactions change during the progression of metastasis is critical to understanding the pathophysiology of this disease...
February 29, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38473273/breast-tumor-metastasis-and-its-microenvironment-it-takes-both-seed-and-soil-to-grow-a-tumor-and-target-it-for-treatment
#39
REVIEW
Shirin Bonni, David N Brindley, M Dean Chamberlain, Nima Daneshvar-Baghbadorani, Andrew Freywald, Denise G Hemmings, Sabine Hombach-Klonisch, Thomas Klonisch, Afshin Raouf, Carrie Simone Shemanko, Diana Topolnitska, Kaitlyn Visser, Franco J Vizeacoumar, Edwin Wang, Spencer B Gibson
Metastasis remains a major challenge in treating breast cancer. Breast tumors metastasize to organ-specific locations such as the brain, lungs, and bone, but why some organs are favored over others remains unclear. Breast tumors also show heterogeneity, plasticity, and distinct microenvironments. This contributes to treatment failure and relapse. The interaction of breast cancer cells with their metastatic microenvironment has led to the concept that primary breast cancer cells act as seeds, whereas the metastatic tissue microenvironment (TME) is the soil...
February 23, 2024: Cancers
https://read.qxmd.com/read/38468823/identification-of-lysyl-oxidase-as-an-adipocyte-secreted-mediator-that-promotes-a-partial-mesenchymal-to-epithelial-transition-in-mda-mb-231-cells
#40
JOURNAL ARTICLE
Cassidy M Van Stiphout, Grant Kelly, Nikitha K Pallegar, Eman Elbakry, Ana Valeria Vilchis-Celis, Sherri L Christian, Alicia M Viloria-Petit
AIM: Breast cancer (BC) is the most common cancer in women worldwide, where adiposity has been linked to BC morbidity. In general, obese premenopausal women diagnosed with triple-negative BC (TNBC) tend to have larger tumours with more metastases, particularly to the bone marrow, and worse prognosis. Previous work using a 3-dimensional (3D) co-culture system consisting of TNBC cells, adipocytes and the laminin-rich extracellular matrix (ECM) trademarked as Matrigel, demonstrated that adipocytes and adipocyte-derived conditioned media (CM) caused a partial mesenchymal-to-epithelial transition (MET)...
2024: Exploration of targeted anti-tumor therapy
keyword
keyword
67814
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.